ELENCO PUBBLICAZIONI PROF. FRANCESCO PISANI
A (riviste internazionali impattate)
1) Cotrufo R., Dattola R., Deodato M., Pisani F., Messina C. "Experimental hyperthyroidism fails to expedite reinnervation of muscles denervated by crushing sciatic nerves in rabbits". Exp.Neurol., 65:271-277,1979.
2) Pisani F., Di Perri R., Nistico' G. "Rapid quantitation of n-dipropylacetamide by gas-liquid chromatography".
J. Chromatogr., 94: 231-233, 1979.
3)Pisani F., Di Perri R. "Some clinical pharmacological aspects of n - dipropylacetamide".
It. J. Neurol. Sci., 4:245-249, 1980.
4)Pisani F., Oteri G., Di Perri R. "Valproic acid fails to displace phenobarbitone and carbamazepine from plasma protein binding sites in epileptic patients". Br.J.Clin.Pharmacol., 12:81-83, 1981.
5) Pisani F., Di Perri R. "Intravenous valproate: effects on plasma and saliva phenytoin levels". Neurology, 31:467- 470, 1981.
6) Pisani F., Fazio A., Oteri G., Di Perri R. "Dipropylacetic acid plasma levels; diurnal fluctuations during chronic treatment with dipropylacetamide". Ther.Drug.Monit., 3:297-301, 1981.
7) Calzetti S., Findley L.J., Pisani F., Richens A. "Phenylethylmalonamide in essential tremor.A double-blind controlled study". J.Neurol.Neurosurg.Psychiatry, 44: 932-934, 1981.
8) Pisani F., Fazio A., Oteri G., Di Perri R. "A study on the metabolism of dipropylacetamide to dipropylacetic acid in rats".
J. Pharm. Pharmacol., 34:45-46, 1982.
9) Cottrell P.R., Streete J.M., Berry D.J., Schafer H., Pisani F., Perucca E., Richens A. "Pharmacokinetics of phenylethylmalonamide (PEMA) in normal subjects and in patients treated with antiepileptic drugs".
Epilepsia, 23:307-313, 1982.
10) PisaniF., Amendola D'Agostino A., Fazio A., Oteri G., Primerano G., Di Perri R. "Increased dipropylacetic acid bioavailability from dipropylacetamide by food". Epilepsia, 23:115-121, 1982.
11) Pisani F., Richens A. "Pharmacokinetics of phenylethylmalonamide (PEMA) after oral and intravenous administration".
Clin.Pharmacokinet., 8:272-276, 1983.
12)Pisani F., Spina E., Trunfio C., Fazio A., Oteri G., Di Perri R.
"Intra-daily oscillations in dipropylacetic acid plasma levels with two or three doses of dipropylacetamide in epileptic patients".
It.J.Neurol.Sci., 2:173-177, 1983.
13) Fazio A., Crisafulli P., Primerano G., Amendola D'Agostino A., Oteri G., Pisani F."A sensitive gas chromatograpic assay for the determination of serum viloxazine concetration using a nitrogen-phosphorus selective detector". Ther. Drug Monit., 6:484-488, 1984.
14) Pisani F., Narbone M.C., Trunfio C., Fazio A., La Rosa G., Oteri G., Di Perri R. "Valproic acid-ethosuximide interaction: A pharmacokinetic study". Epilepsia, 25:229-233,1984.
15) Pisani F., Perucca E., Primerano G., Amendola D'Agostino A., Petrelli R.M., Fazio A., Oteri G., Di Perri R. "Single-dose kinetics of primidone in acute viral hepatitis". Eur.J.Clin.Pharmacol., 27:465-469, 1984.
16) Pisani F., Narbone M.C., Fazio A., Crisafulli P., Primerano G., Amendola D'Agostino A., Oteri G., Di Perri R. "Effect of viloxazine on serum carbamazepine levels in epileptic patients".
Epilepsia, 25:482-485, 1984.
17) Pisani F., Primerano G., Amendola D'Agostino A., Spina E., Fazio A. "Valproic acid-amitriptyline interaction in man".
Ther. Drug. Monit., 8:382-384, 1986.
18) Pisani F., Fazio A., Spina E., Artesi C., Pisani B., Russo M., Trio R., Perucca E. "Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment". Psychopharmacology, 90: 295-298, 1986.
19) Pisani F., Fazio A., Oteri G., Perucca E., Russo M., Trio R., Pisani B., Di Perri R. "Carbamazepine-viloxazine interaction in patients with epilepsy". J.Neurol.Neurosurg. Psichiatry. 49:1142-1l 45, 1986.
20) Pisani F., Fazio A., Oteri G.,Ruello C.,Gitto C.,Russo F. & Perucca E. "Sodium valproate and valpromide:Differential interactions with carbamazepine in epileptic patients". Epilepsia, 27:548-552, 1986.
21) Spina E., Arena A., Pisani F. "Urinary desipramine hydroxylation index and steady-state plasma concentrations of imipramine and desipramine". Ther. Drug. Monit., 9: 129-133, 1987.
22) Fazio E., Spina E., Pisani F. "Tricyclic antidepressant analysis by liquid chromatography". J. Liquid Chromatogr., 10:223-240, 1987.
23) Pisani F.,Fazio A., Artesi C., Oteri G., Pisani B., Perucca E.,
Di Perri R. "An epidemiological study of the clinical impact of pharma=
cokinetic anticonvulsant drug interactions based on serum
drug level analysis". It. J.Neurol.Sci., 8:135-142, 1987.
24) Fazio A., Artesi C., Oteri G., Romano F., Russo M., Spina E., Trio R.,
Pisani F. "Evaluation of Tricyclic Antidepressant Plasma Levels by an Automated Enzyme Immunoassay (EMIT) in Comparison to a High-Performance Liquid Chromatographic Method".
Ther. Drug. Monit., 10:333-339, 1988.
25) Pisani F., Fazio A., Oteri G., Spina E., Perucca E., Bertilsson L.
"Effect of valpromide on the pharmacokinetics of Carbamazepine-10,11-epoxide". Br.J.Clin.Pharmac.,25: 611-613, 1988.
26) Perucca E.,Pisani F.,Spina E.,Oteri G.,Fazio A. & Bertilsson L.
"Effects of valpramide and viloxazine on the eliminatian of carbamazepine-
10-11-epoxide,an active metabolite of carbamazepine".
Pharmacol. Res. 21:111-112, 1989.
27) Pisani F., Perucca E., Di Perri R. "Clinically relevant antiepileptic
drug interactions". J. Int. Med. Res. 18:1-15, 1990.
28) Canger R., Altamura A.C., Belvedere O., Monaco F., Monza G.C., Muscas, G.C., Mutani R., Panetta B., Pisani F., Zaccara G., Zagnoni P.G. "Conventional vs controlled-release carbamazepine: a multicenter, double-blind, cross-over study". Acta Neurol. Scand., 82: 9-13, 1990.
29) Fazio A., Perucca E., Pisani F. "Liquid chromatographic analysis of antiepileptic drugs: An overview". J. Liquid Chromat., 13: 3711-3740,1990.
30) Bialer M., Haj-Yehia A., Pisani F., Perucca E.
"Pharmacokinetics of a valproic acid isomer, valnoctamide, in healthy subjects". Eur. J. Clin. Pharmacol. 38:289-291, 1990.
31) Pisani F., Caputo M., Fazio A., Oteri G., Russo M., Spina E., Perucca E., Bertilsson L. "Interaction of carbamazepine-10,11-epoxide,an active,metabolite of carbamazepine,with valproate : a pharmacokinetic study". Epilepsia 31:339-342, 1990.
32) Spina E., Amendola D'Agostino A.M., Ioculano M.P., Oteri G., Fazio A., Pisani F. "No effect of thioridazine on plasma concentrations of carbamazepine and its active metabolite carbamazepine-10,11-epoxide". Ther. Drug. Monit., 12:511-513, 1990.
33) Pisani F., Gallitto G., Di Perri R. “May lamotrigine be useful in status epilepticus? A case report".
J. Neurol. Neurosurg. Psychiatry, 54:845-846, 1991.
34) Defazio G., Lepore V., Specchio L.M., Pisani F., Livrea P.
"The influence of electroencephalographic focus laterality on efficacy of Carbamazepine in complex partial and secondarily generalized tonic-clonic seizures". Epilepsia, 32:706-711, 1991.
35) Spina E., Martines C., Fazio A., Trio R., Pisani F., Tomson T.
"Effect of phenobarbital on the pharmacokinetics of carbamazepine- 10,11-epoxide, an active metabolite of carbamazepine".
Ther. Drug.Monit., 13:109-112, 1991.
36) Pisani F., Fazio A., Artesi C., Russo M., Trio R., Oteri G., Perucca E., Di Perri R. "Elevation of plasma phenytoin by viloxazine in epileptic patients: A clinically significant drug interaction".
J. Neurol. Neurosurg. Psychiatry, 55:126-127,1992.
37) Fazio A., Artesi C.,Russo M., Trio R., Oteri G.,Perucca E., Pisani F. "Liquid chromatographic assay of lamotrigine,a new antiepileptic drug, by a hig-speed column". Ther. Drug. Monit. 14:509-512, 1992.
38) Pisani F., Russo M., Trio R., Oteri G., Spina E., Tomson T., Perucca E. " Impairment of carbamazepine-10,11 epoxide elimination by valnoctamide, a valpromide isomer, in healthy subjects".
Br. J. Clin. Pharmacol. 34/ 1:85-87,1992.
39) Pisani F. " Influence of co-medication on VPA metabolism".
Pharm. Weekbl. 14/3A: 108-113,1992.
40) Angeleri F., Scarpino O., Avanzini G., Binelli D., Baruzzi A., Procaccianti G., Bergamasco B., Bianco C., Canger R., Mai R., Di Perri R., Pisani F., Loeb C., Cocito L., Manfredi N., Faedda M.T., Mutani R., Ianelli M., Tartara A., Perucca E., Tassinari C.A., Michelucci R., Zappoli R., Zaccara G., Gnanasakthy A., Iudice A., Matthews J., Mumford J.P. " Single-blind, placebo-controlled multicenter trial of Vigabatrin in the treatment of epilepsy". Ital. J. Neurol. Sci. , 13: 741-747, 1992.
41) Spina E., Avenoso A., Pollicino A.M., Caputi A.P., Fazio A., and Pisani F. " No modification in plasma levels of carbamazepine and its epoxide metabolite during coadministration of fluoxetine or fluvoxamine".
Ther. Drug. Monit., 15: 247-250,1993
42) Pisani F.,Haj-Yehia A., Fazio A., Artesi C., Oteri G., Perucca E., Levy R.H., Bialer M. "Carbamazepine-valnoctamide interaction in epileptic patients: in vitro/in vivo correlation". Epilepsia,34:954-959, 1993.
43) Spina E., Avenoso A., Pollicino A.M., Caputi A.P., Fazio A., Pisani F. "Carbamazepine coadministration with Fluoxetine or Fluvoxamine".
Ther. Drug. Monit., 15:247-250, 1993.
44) Gatti G., Bartoli A., Michelucci R., Tassinari C.A., Pisani F., Zaccara G., Timmings P, Richens A., Perucca E. "Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability". Br. J. Clin. Pharmacol., 36:603-606, 1993.
45) Pisani F., Di Perri R., Perucca E., Richens A. "Interaction of lamotrigine with sodium valproate". The Lancet 341:1224, 1993.
46) Battino D., Buti D., Croci D., Estienne M., Fazio A., Granata T.,
Pisani F., Rota M., Avanzini G. "Lamotrigine in resistant childhood epilepsy". Neuropediatrics, 24:332-336, 1993.
47) Pisani F., Fazio A., Oteri G., Artesi C., Xiao B. Perucca E., Di Perri R. "Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy".
Acta Neurol. Scand., 90:130-132, 1994.
48) Zagnoni P.G., Bianchi A., Zolo P., Canger R., Cornaggia C., D'Alessandro P., De Marco P., Pisani F., Gianelli M., Verzè L., Viani F. & Zaccara G. "Allopurinol as add-on therapy in refractory epilepsy: A double-blind placebo-controlled randomized study".
Epilepsia, 35:107-112, 1994.
49) Pisani F., Xiao B., Fazio A., Spina E., Tomson T.
"Single dose pharmacokinetics of Carbamazepine-10,11-epoxide in patients on Lamotrigine monotherapy". Epilepsy Res., 19:245-248, 1994.
50) Giaccone M., Bartoli A., Gatti G., Marchiselli R., Pisani F., Latella M.A., Perucca E. "Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients".
Br. J. Clin. Pharmacol. 41:575-579, 1996.
51) Spina E., Pisani F., Perucca E.
"Clinically significant pharmacokinetic drug interactions with carbamazepine. An update". Clin. Pharmacokinet. 31:198-214, 1996.
52) Avanzini G., Canger R., Dalla Bernardina B., (altri autori), Pisani F., (altri autori). “Felbamate in therapy-resistant epilepsy: an Italian experience”. Epilepsy Res. 25:249-255, 1996.
53) Beghi E., Cornaggia C., (altri autori),Pisani F., (altri autori). "Epilepsy and everyday life risks". Neuroepidemiology 16:207-216, 1997.
54) Barel S., Yagen B., Schuring V., Soback S., Pisani F., Perucca E. & Bialer M. " Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and patients with epilepsy".
Clin.Pharmacol. Ther. 61:442-449, 1997.
55) Spina E., Arena D., Scordo M.G., Fazio A., Pisani F., Perucca E.
"Elevation of plasma carbamazepine concentrations by ketoconazole in patients with epilepsy". Ther. Drug Monit. 19: 535-538, 1997.
56) Battino D., Croci D., Granata T., Estienne M., Pisani F., Avanzini G."Lamotrigine plasma concentrations in children and adults: Influence of Age and associated therapy". Ther. Drug Monit. 19: 620-627, 1997.
57) Chadwick D, Beghi E., Callaghan N., de Bittencourt P., Dulac O., Gram L., Johonson A.L., Mattson R., Pisani F., Porter R.J., Richens A., Schimdt D., van Donselaar C.A. “Report of the ILAE Commision on Antiepileptic Drugs. “Considerations on Designing Clinical Trials to Evaluate the Place of New Antiepileptic Drugs in the Treatment of Newly Diagnosed and Chronic Patients with Epilepsy”. Epilepsia 39:799-803, 1998.
58) Chadwick D., (altri autori), Pisani F., (altri autori).“Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre
randomised double-blind study. Vigabatrin European Monotherapy Study
Group. TheLancet 354(9172): 13-19, 1999.
59) Pisani F., Oteri G., Russo MF, Di Perri R, Perucca E, Richens A.
"The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction".
Epilepsia 40:1141-1146, 1999. (già citato nell’elenco)
60) Pisani F., Spina E., Oteri G. "Antidepressant drugs and seizure susceptibility. From in vitro data to clinical practice".
Epilepsia 40:48-56, 1999.(già citato nell’elenco)
61) The RESt-1 Group, Beghi E, (altri autori), Pisani F., Oteri G., (altri autori)“Social Aspects of epilepsy in the adult in seven european countries”.
Epilepsia 41:998-1004, 2000.
62) Pisani F. , Pedale S., Macaione V., D'angelo R., Oteri G., Macaione S. and Ientile R. “Neuroprotective effects of lamotrigine and remacemide on excitotoxicity induced by glutamate agonists in isolated chick retina”.
Exp. Neurol. 170:162-170, 2001. (già citato nell’elenco)
63) Pisani F., Oteri G., Costa C., Di Raimondo G. , Di Perri R. “Effect of psychotropic drugs on seizure threshold”. Drug Safety 25: 91-110, 2002.
64)Patsalos P.N., Froscher W., Pisani F., and van Rijn C.M.
“The importance of drug interactions in epilepsy therapy”.
Epilepsia 43:365-385, 2002. (già citato nell’elenco)
65) Beghi E., Cornaggia C., (altri autori), Pisani F., Oteri G. (altri autori)..”Morbidity and accidents in patients with epilepsy: Results of a European cohort study”. Epilepsia 43:1076-1083, 2002.
67) Calabresi P., Centonze D., Cupini L.M., Costa C., Pisani F., Bernardi G.
“Ionotropic glutamate receptors: still a target for neuroprotection in brain ischemia ? Insight from in vitro studies.
Neurobiology of Disease 12:82-88,2003. (già citato nell’elenco)
68) Calabresi P., Cupini L.M., Centonze D., Pisani F., Bernardi G.
Antiepileptic drugs as a possible neuroprotective strategy in brain
Ischemia. Ann. Neurol. 53: 693-702, 2003. (già citato nell’elenco)
69) Pisani F., Costa C., Oteri G., and Ioli A. “Identification of amoebae in the CSF in a patient with meningoencephalitis.
J.Neurol., Neurosurg. Psichiatry 74:1445-1446,2003. (già citato nell’elenco)
70) Calabresi P., Marti M., Picconi B., Saulle E., Centonze D., Pisani F., and Bernardi G. “Lamotrigine and Remacemide protect striatal neurons against in vitro ischemia: an electrophysiological study”.
Exp. Neurol. 182: 461-469, 2003.(già citato nell’elenco)
71) Marini H., Costa C., Passaniti M., Esposito M., Campo G.M., Ientile R., Adamo E.B., Marini R., Calabresi P., Altavilla D., Minatoli L., Pisani F., Squadrito F. “Levetiracetam protects against kainic acid-induced toxicity”.
Life Sciences74: 1253-1264, 2004.
72) Costa C., Leone G., Tropepi D., Pisani F., Bernardi G., Calabresi P. “Coactivation of GABAA and GABAB receptors is required for the GABA-mediated neuroprotection against in vitro ischemia”.
Stroke 35:596-600, 2004.(già citato nell’elenco)
74)Pisani A., Bonsi P., Martella G., De Persis C., Costa C., Pisani F.,
Bernardi G., Calabresi P. Intracellular calcium rise in epileptiform activity:
modulation by Levetiracetam and Lamotrigine. Epilepsia 45:719-728, 2004.
(già citato nell’elenco)
75)van den Broek M., Beghi E., altri AA, Pisani F., Oteri G., alti AA.
Morbidity in patients with epilepsy: type and complications: a European
cohort study.Epilepsia45(1):71-76, 2004.
76)van den Broek M., Beghi E., altri AA, Pisani F., Oteri G., alti AA.
Accidents in patients with epilepsy: types, circumstances, and complications: a European cohort study.Epilepsia. 45(6):667-72, 2004.
77) Caccamo D., Condello S., Gorgone G., Crisafulli G., Belcastro V., Gennaro S, Striano P., Pisani F. and Ientile R. “Screening for C677T and A1298C MTHFR polymorphisms in patients with epilepsy and risk of hyperhomocysteinemia.Neuromolecular Medicine 6:117-126, 2004.
(già citato nell’elenco)
78) Pisani F., Costa C., Caccamo D., Mazzon E., Gorgone G., Oteri G., Calabresi P. and Ientile R. “Tiagabine and vigabatrin reduce NMDA-induced excitotoxicity in chick retina”. Exp. Brain Res.17:511-515, 2006.
(già citato nell’elenco)
79) Costa C., Martella G, Pisani A., Pisani F., Bernardi G. and Calabresi P.
Multiple mechanisms underlying the neuroprotective effects of antiepileptic
drugs against in vitro ischemia. Stroke37:1319-1326, 2006.
(già citato nell’elenco)
80) Ferlazzo E, Raffaele M, Mazzù I, and Pisani F. Recurrent status
epilepticus as the main feature of Hashimoto’s encephalopathy.
Epilepsy & Behaviour 8:328-330, 2006. (già citato nell’elenco)
81) Striano S., Striano P., Di Nocera P., Bilo L., Ruosi P., Coppola A., Fastello C. and Pisani F. “Usefulness of MHD monitoring in managing side effects of high-doses oxc therapy in drug-resistant partial epilepsy”
Epilepsy Res.69:170-176, 2006. (già citato nell’elenco)
82) Drago, V., Jeong, Y., Crucian, G. P., FitzGerald, D. B., Finney, G. R., Mizuno, T., Pisani, F., & Heilman, K. M. Ipsilesional attentional-approach neglect or crossover effect. Neurocase, 12:207-211 2006.
83) Drago V, Crucian GP, Pisani F., Heilman KM. Distribution of attention
in normal people as a function of spatial location:right-left, up-down. J Int
Neuropsychol Soc. 12(4):532-7, 2006.
84)Drago V, Crucian GP, Foster PS, Cheong J, Finney GR, Pisani F,
Heilman KM. Lewy body dementia and creativity: Case report.
Neuropsychologia. 44(14):3011-3015, 2006.
85)Caccamo D., Gorgone G., Currò M., Parisi G., Di Iorio W.,
Menichetti C., Belcastro V., Rossi A., Pisani F., Ientile R., and Calabresi
P.Effect of MTHFR polymorphisms on hyperhomocysteinemia in
levodopa-treated parkinsonian patients.
Neuromolecular Medicine 9 (3): 249-254, 2007.(già citato nell’elenco)
86) Belcastro V., Gorgone G., Italiano D., Oteri G., CaccamoD., Pisani
L.R., Striano P., Striano S., Ientile R., and Pisani F. Antiepileptic drugs
and MTHFR polymorphisms influence hyperhomocysteinemia recurrence
in epileptic patients. Epilepsia 48(10):1990-1994, 2007.
(già citato nell’elenco)
87) Belcastro V., Costa C., Galletti F., Pisani F., Calabresi P., Parnetti
L.Levetiracetam monotherapy in Alzheimer patients with late-onset
seizures:a prospective observational study.
Eur J Neurol. 14(10):1176-8, 2007.
88) Bilo L., Meo R., De Leva M.F., Ruosi P., De Simone R., Pisani F.,
Striano S. Levetiracetam in epileptic patients with chronic liver disease:
observations in a case series.Clin. Neuropharmacol. 31:221-225, 2008.
89) Belcastro V, Striano P, Caccamo D, Costa C, Pisani LR, Trombetta
CJ, Maddaloni A, Ciampa C, Reccia R, Ientile R, Striano S, Calabresi P,
Pisani F. Hyperhomocysteinemia and retinal vascular changes in patients
with epilepsy. Epilepsy Research81:86-89, 2008(già citato nell’elenco)
90) Striano S, Striano P, Capone D, Pisani F. Limited place for plasma
monitoring of new antiepileptic drugs in clinicalpractice.
Med Sci Monit. 14(10):RA173-8, 2008.
91)Belcastro V, Striano P, Ciampa C, Pierguidi L, Napoli M, Freno MC,
Tenore R,Striano S, Pisani F, Trombetta CJ.Is retinal assessment useful in
epileptic patients with hyperhomocysteinemia? Eye 23:1532-1534, 2009.
92) Gorgone G, Ursini F, AltamuraC, Bressi F, Tombini Ma, Curcio G,
Chiovenda P, Squitti R, Silvestrini M, Ientile R, Pisani F, Rossini PM,
Vernieri F. Hyperhomocysteinemia, intima-media thickness and C677T
MTHFR gene polymorphism: a correlation study in patients with cognitive
impairment. Atherosclerosis 209:309-313, 2009. (già citato nell’elenco)
93) Gorgone G, Caccamo D, Pisani LR, Curro` M, Parisi G, Oteri G,
Ientile R, Rossini PM, and Pisani F. Hyperhomocysteinemia in patients
with epilepsy: Does itplay a role in the pathogenesis of brain atrophy?
A preliminary report. Epilepsia 50:33-36, 2009. (già citato nell’elenco)
94) Pierguidi L, Belcastro V, Castrioto A, Menichetti C, Ientile R,
Pisani F, Rossi A,Calabresi P, Tambasco N. Hyperhomocysteinemia
recurrence in levodopa treated Parkinson’s disease patients.
Eur. J. Neurol., 2009 (in stampa).
95) Belcastro V, Striano P, Gorgone G, Costa C, Campa C, Caccamo D, Pisani LR, Oteri G, Marciani MG, Aguglia U, Striano S, Ientile R, Calabresi P, Pisani F. Hyperhomocysteinemia in epileptic patients on newantiepileptic drugs. Epilepsia 2009 (in stampa)
* * *
B (Capitoli di volumi a diffusione internazionale)
96) Musolino R., Gallitto G., Morgante L., Pisani F., Nistico' G.,
Di Perri R. "Depamide:a preliminary report on its therapeutic efficacy in
epilepsy".In: Epilepsy:A clinical and experimental reasearch. Manogr.
Neurol. Sci., Vol.5, Karger, Basel, pp. 124-130, 1980.
97) Pisani F., Fazio A.,Oteri G.,Ruello C., Gitto C., Russo F., Perucca
E."Differential interactions of valproic acid and valpromide with
Carbamazepine in man". Advances in Epileptology, vol.16, Raven Press,
New York, pp. 431-433, 1987.
98) Perucca E. & Pisani F. "Dose-response relationship and therapeutic
drug monitoring". In:"Dose-response relationship in clinical
pharmacology", L.Lasagna, S. Erill,C.A., Naranio (Eds.), Elsiever
Science Publishers, pp.201-214, 1989.
99) Canger R., Cornaggia C.M., Monaco F., Monza G.C., Pisani F.,
Zaccara G., Zagnoni P.G."Clinical and pharmacokinetic study of
conventionalcarbamazepine vs a new controlled-release (CR) formulation:
a double-blind,cross-over trial". Advances in Epileptology, vol 17,
Raven Press, New York, pp.201.204, 1989.
100) Pisani F.,Oteri G.,Caputo M.,Di Perri R. "Diurnal fluctuations in
plasmadrug levels:studies with valproic acid andcarbamazepine". In:
Chronopharmacology in therapy of the epilepsies. F.E. Dreifuss, H.
Meinardi. H. Stefan (Ed.), Raven Press, New York, pp. 129-144, 1990.
101) Perucca E., Pisani F. "Pharmacokinetics and interactions of the new
antiepileptic drugs". In: Pisani F., Perucca E., Avanzini G., Richens A.
(Eds.), New Antiepileptic drugs:A challenge for the future, Elsevier
Science Publishers, pp.79-88, 1991.
102) Pisani F., Russo M., Trio R., Artesi C.,Fazio A., Oteri G., Di Perri R.
"Lamotrigine in refractory epilepsy: A long-term open study".
In: Pisani F., Perucca E., Avanzini G., Richens A. (Eds.),
New Antiepileptic drugs:A challenge for the future, Elsevier
Science Publishers, pp.187-191, 1991.
103) Pisani F. " Pharmacokinetics of Lamotrigine. In: Lamotrigine- a new
advance in the treatment of epilepsy. Edited by E.H. Reynolds, Royal
Society of Medicine Services Limited London, New York, pp. 15-23, 1993
104) Pisani F., Bialer M. "Ethosuximide: chemistry and
biotransformation".In: Antiepileptic Drugs ( fourth Edition), Edithors:
Levy R.H., Mattson R.H.,Meldrum B.S., Raven Press, New York, pp.
655-658, 1995.
105) Pisani F. "Pharmacokinetics of Lamotrigine". In: Lamotrigine - A
brighter future, Edited by P. Loiseau, The Royal Society of Medicine
PressLimited, 214: 3-7, 1996.
106) Pisani F., Di Perri R. "Antiepileptic drug comedications in clinical
practice". In: Molecular and cellular targets for antiepileptic drugs, ed. G.
Avanzini et al., John Libbey & Company Ltd., pag. 255-261, 1997.
107) Pisani F. “Pharmacokinetics and therapeutic plasma monitoring of
antiepileptic drugs”.In: Handbook of Clinical Neurology, The
Epilepsies,P.J. Vinken and G.W. Bruyn (Eds.), vol 73, cap 27, pp
357- 368;Elseviers Publishers, 2000.
108) Pisani F.and Richens A. “Lamotrigine: Toxicity”. In:
AntiepilepticDrugs, V Edition, Levy R.H., Mattson R. H., Meldrum
B.S., Perucca E. (Eds), Lippincott Wlliams & Wilkins (U.S.A.),
chapter 39, pp. 408-416, 2002.
109) Pisani F., Perucca E., and Bialer M. “Ethosuximide:Chemistry,
Biotransformation, Pharmacokinetics and Drug Interaction”. In:
Antiepileptic Drugs, V Edition, Levy R.H., Mattson R. H., Meldrum
B.S., Perucca E. (Eds), Lippincott Wlliams & Wilkins (U.S.A.),
chapter 67, pp. 646-651, 2002.
(co-editor libro internazionale)
110) Pisani F., Perucca E., Avanzini G., Richens A. New
Antiepilepticdrugs. Elsevier Science Publishers, pp.196, 1991.
C (pubblicazioni su riviste a diffusione nazionale)
111) Messina C., Cotrufo R., Cardia E., Dattola R., Deodato
M., Pisani F. "Rilievi elettrofisiologici sulla velocita' di
rigenerazione, dopo axanotmesi, del nervo sciatico di coniglio in corso di trattamento con triiodotiranina, citicolina, gangliosidi cerebrali bovini". Riv.It.EEG Neurofis.Clin.,1:77-81,1978.
112) Cotrufo R., Dattola R., Deodato M., Pisani F., Messina C.
"Risultati preliminari di uno studio sperimentale sulla veloci=
ta' di rigeneraziane del nervo sciatico in corso di trattamento
con triiodotironina, gangliosidi cerebrali bovini o citicolina.
Clinica Terapeutica, 94:561-656,1980.
113) Musolino R., Gallitto G., Morgante L., Pisani F., Di Perri R. " The antiepileptic properties of n-dipropylacetamide
(Depamide). A clinical trial". Acta Neurol., 35:107-114, 1980.
114) Musolino R., Natoli M., Gallitto G., Morgante L., Serra S., Pisani F, .Di Perri R. "The effect of chronic n-dipropylacetamide (Depamide) on plasmatic immunoglobulins of epileptic patients". Acta Neurol., 35:115-120, 1980.